SARS-CoV-2 seropositivity after infection and antibody response to mRNA-based vaccination
Ciccone, E. J.; Zhu, D. R.; Ajeen, R.; Shook-Sa, B. E.; Boyce, R. M.; COVID HCW Study Team, ; Aiello, A. E.
Show abstract
The effect of SARS-CoV-2 seropositivity on the immune response to mRNA-based SARS-CoV-2 vaccines has not been well-described. Here we report longitudinal SARS-CoV-2-specific antibody responses pre- and post-vaccination among a cohort of healthcare personnel, with and without prior infection, from a large academic medical center. Our results provide preliminary evidence that prior SARS-CoV-2 infection may prime the response to the first mRNA-based SARS-CoV-2 vaccine dose. These findings could have significant impact on the allocation of mRNA-based vaccines and support the need for future research into the effect of prior infection on magnitude and durability of vaccination response.
Matching journals
The top 6 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Effectiveness of mRNA COVID-19 vaccines and hybrid immunity in preventing SARS-CoV-2 infection and symptomatic COVID-19 among adults in the United States 94%
- Correlation between post-vaccination titres of combined IgG, IgA, and IgM anti-Spike antibodies and protection against breakthrough SARS-CoV-2 infection: a population-based longitudinal study (COVIDENCE UK) 94%
- People with HIV receiving suppressive antiretroviral therapy show typical antibody durability after dual COVID-19 vaccination, and strong third dose responses 94%
Similar papers in this journal
- Immunogenicity of a third dose of BNT162b2 to ancestral SARS-CoV-2 & Omicron variant in adults who received two doses of inactivated vaccine 95%
- Single-dose mRNA vaccine effectiveness against SARS-CoV-2 in healthcare workers extending 16 weeks post-vaccination: a test-negative design from Quebec, Canada 94%
- Coronavirus Disease 2019 (COVID-19) Vaccine Boosting in Persons Already Protected by Natural or Vaccine-Induced Immunity 94%
Similar papers in this journal
- Adverse effects and antibody titers in response to the BNT162b2 mRNA COVID-19 vaccine in a prospective study of healthcare workers 96%
- Impact of previous COVID-19 on immune response after a single dose of BNT162b2 SARS-CoV-2 vaccine 94%
- Effectiveness of the Coronavirus Disease 2019 (COVID-19) Bivalent Vaccine 94%
Similar papers in this journal
- Impact of prior SARS-CoV-2 infection on post-vaccination SARS-CoV-2 spike IgG antibodies in a longitudinal cohort of healthcare workers 96%
- Protection afforded by the BNT162b2 and mRNA-1273 COVID-19 vaccines in fully vaccinated cohorts with and without prior infection 94%
- Single Dose Vaccination in Healthcare Workers Previously Infected with SARS-CoV-2 93%
Similar papers in this journal
- Durability of the immune response to a third BNT162b2 dose; five months follow-up 95%
- Real-world effectiveness of Ad26.COV2.S adenoviral vector vaccine for COVID-19 93%
- Effectiveness of the BNT162b vaccine fourth dose in reducing SARS-CoV-2 infection among healthcare workers in Israel, a multi-center cohort study 93%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.